Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study
| dc.contributor.author | Markatseli, T. E. | en |
| dc.contributor.author | Alamanos, Y. | en |
| dc.contributor.author | Saougou, I. | en |
| dc.contributor.author | Voulgari, P. V. | en |
| dc.contributor.author | Drosos, A. A. | en |
| dc.date.accessioned | 2015-11-24T18:49:13Z | |
| dc.date.available | 2015-11-24T18:49:13Z | |
| dc.identifier.issn | 0392-856X | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/17949 | |
| dc.rights | Default Licence | - |
| dc.title | Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study | en |
| heal.abstract | OBJECTIVES: To investigate the efficacy, safety and survival of tumour necrosis factor (TNF) alpha antagonists in patients with rheumatoid arthritis (RA). METHODS: One hundred and fifty-one RA patients treated with TNF-alpha inhibitors during the time period 2000 to 2009 were studied. Kaplan-Meier statistic analysis was applied, in which discontinuation from anti-TNF-alpha therapy was used as the terminal event. RESULTS: Eighty-two patients received infliximab, 49 adalimumab and 20 etanercept: they were followed up over 7, 5 and 4 years, respectively. Anti-TNF-alpha therapy resulted in a rapid clinical improvement associated with a reduction in inflammatory markers in the first year of the treatment, which was sustained throughout the following years. Ninety (59.6%) patients were withdrawn during the observational period overall. The patients who discontinued infliximab, adalimumab and etanercept therapy were 55/82 (67.1%), 27/49 (55.1%) and 8/20 (40%) respectively. The main reasons for discontinuation were drug adverse events and inefficacy. According to Kaplan-Meier methods, the 'survival rate' of infliximab after the first year of treatment reached 82.9%, while after 7 years the proportion was 32.9%. With regard to adalimumab, after the first year of treatment its 'survival rate' was 83.7% and after 5 years it reached 44.9%. As far as etanercept is concerned, after the first year of treatment, the 'survival rate' reached 70% and after 4 years it remained 60%. CONCLUSIONS: TNF-alpha antagonists constitute an effective therapeutic option for patients with RA refractory to disease-modifying anti-rheumatic drugs. They demonstrate an acceptable safety profile. Their survival rate is high in the first years of treatment, while after the fifth year it decreases considerably. | en |
| heal.access | campus | - |
| heal.fullTextAvailability | TRUE | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/22153557 | - |
| heal.journalName | Clin Exp Rheumatol | en |
| heal.journalType | peer-reviewed | - |
| heal.language | en | - |
| heal.publicationDate | 2012 | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.type | journalArticle | - |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.type.en | Journal article | en |
Αρχεία
Φάκελος/Πακέτο αδειών
1 - 1 of 1
Φόρτωση...
- Ονομα:
- license.txt
- Μέγεθος:
- 1.74 KB
- Μορφότυπο:
- Item-specific license agreed upon to submission
- Περιγραφή: